Teplizumab BLA Re-submission Accepted by FDA; March 21-24 CHMP Agenda

Two cardiometabolic-related news items have been observed: Provention Bio announced FDA has accepted the resubmitted teplizumab BLA for the delayed onset of T1DM; and the CHMP agenda for this month’s meeting (March 21-24) has been released. Below, FENIX provides highlights and insights for the respective new items.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.